# Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)

> **NCT01189526** · PHASE3 · UNKNOWN · sponsor: **Seoul Retina Investigator Group** · enrollment: 60 (estimated)

## Conditions studied

- Branch Retinal Vein Occlusion

## Interventions

- **DRUG:** Ranibizumab
- **PROCEDURE:** macular laser photocoagulation

## Key facts

- **NCT ID:** NCT01189526
- **Lead sponsor:** Seoul Retina Investigator Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-01
- **Primary completion:** 2010-08
- **Final completion:** 2011-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2010-08-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01189526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01189526, "Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01189526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*